BSE Code - 500087
Face Value - Rs 2.00
Group - BSE 'A'
Shareholding pattern - (a)Promoters - 36.80%
(b)Institutions - 35.86%
(c)Non-Institutions - 26.23%
One year High-Low - Rs 576.50 - Rs 366.70
Cipla, a global pharmaceutical company, has collaborated with S&D Pharma in the Czech Republic and Slovakia. This collaboration will enable Cipla to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.
Under the collaboration, Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head. S&D Pharma will physically distribute all products, including respiratory products, and this portfolio will increase over the next few years.
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.
Stock is currently trading at Rs 574.00, up by 10.60 points from its previous closing of Rs 563.40 on the BSE.
No comments:
Post a Comment